Boehringer Ingelheim has signed a drug discovery collaboration and licensing agreement with Domain Therapeutics for the development of new drugs to treat central nervous system (CNS) diseases.
5 December 2018 News
30 November 2018 Comment
Alzheimer’s disease is a complex and poorly understood disorder that ultimately leads to neurodegeneration in patients afflicted with the disease.
30 November 2018 News
Scientists from Feinstein Institute for Medical Research in the US have revealed that a gene therapy called AAV2-GAD for Parkinson’s disease will create new brain circuits for motor function.
23 November 2018 News
Swedish research-based pharmaceutical and biotechnology company Camurus has received European Commission (EC) approval for weekly and monthly Buvidal injections to treat opioid dependency in adults and teenagers from 16 years...
16 November 2018 News
AbbVie has collaborated with UK-based drug discovery firm Mission Therapeutics for research and preclinical development of potential therapies to treat Alzheimer’s disease and Parkinson’s disease.
8 November 2018 News
A new study led by the Centenary Institute in Australia has demonstrated the use of cancer drug Ponatinib as a potential treatment for cerebral cavernous malformations (CCM) in young individuals.
20 September 2018 projects
Germany-based pharmaceutical company, Boehringer Ingelheim, is constructing a new tablet production facility in Ingelheim, Germany, with an estimated investment of more than €85m ($97.2m).
16 March 2018 projects
Eisai China has built a new oral solid dose (OSD) production facility at its new Suzhou plant in China.
29 July 2013 projects
Dainippon Sumitomo Pharma (DSP) opened a new chemistry research building in Osaka, Japan, in June 2013.